STOKE THERAPEUTICS INC (STOK)
Health Care · Genetic disease therapeutics / protein upregulation · NASDAQ
Stoke Therapeutics uses its proprietary TANGO protein upregulation platform to develop treatments for severe genetic diseases, with lead candidate zorevunersen in clinical trials for Dravet syndrome.
What STOKE THERAPEUTICS INC does
Stoke Therapeutics is a late-stage clinical biopharmaceutical company focused on developing treatments for severe genetic diseases by upregulating protein expression using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. The company's lead candidate, zorevunersen (STK-001), is in clinical development for Dravet syndrome, while STK-002 is being developed for other indications. The company also collaborates with Biogen and Acadia Pharmaceuticals to expand its pipeline of protein upregulation-based product candidates.
Themes: ["genetic disease treatment","protein upregulation platform","rare seizure disorders","gene expression modulation"]
Fundamentals
- Price$32.83 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+173.1% as of 2026-07-09 close
- Net margin-529.2% as of 2026-07-10
- ROE-48.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-83.2% as of 2026-07-10
- Revenue CAGR (3y)+145.9% SEC XBRL
- Beta1.20 as of 2026-07-10
Key risks (from latest filing)
["Limited operating history and ability to achieve profitability with significant ongoing R&D expenses and unprofitable operations","Clinical development risk: early preclinical or clinical trial success may not translate to later-stage efficacy or regulatory approval for zorevunersen, STK-002, or future candidates","Dependence on collaboration partners (Biogen and Acadia) and reliance on third-party intellectual property licensing, with market access dependent on reimbursement and patient identification"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.